Lipidomic Biomarkers Assay
Biomarkers are measurable indicators of normal biological processes, pathogenic processes or pharmacological responses to therapeutic intervention. Biomarkers could be used to support the presence or absence of specific diseases (diagnostic biomarkers), provide individualized treatment (treatment biomarkers), measure treatment progress (treatment response biomarkers) and predict the onset of upcoming disease (predictive biomarkers).
Lipids are the fundamental components of biological membranes as well as the metabolites of organisms. Lipids play diverse and important roles in biologicals. The lipid imbalance is closely associated with numerous human lifestyle-related diseases, such as atherosclerosis, obesity, diabetes, and Alzheimer's disease. Lipidomics elucidates the way lipids are metabolized by studying their composition, structure and quantification in biological samples, and can be used to find biomarkers and to study the mechanisms of action of lipid molecules at the aggregate level in various life phenomena.
Fig1. Biomarker impacts all aspects of drug development and modern medicine (Bakhtiar, Ray, 2008)
Lipidomics can explore the lipid biomarkers that cause lesions in organisms or are expressed abnormally in disease states of organisms, analyze their changes throughout the lesion process and their interactions with other biomolecules, grasp the position of lipid metabolism disorders in the development of diseases from a holistic perspective, and find possible pathogenic mechanisms. In addition, disease biomarkers can also provide ideas for drug development.
The advantage of the lipidomics approach is that lipids can be considered as intermediate phenotypes closer to the relevant disease states than, for example, genetic information. Thus, it is possible to demonstrate a strong association between molecular lipid species and disease states even with relatively small sample sets compared to genetic association studies.
- Drug target and lead compound discovery
Lipidomics provides a platform to study lipid-lipid interactions and lipid-protein interactions in disease states, and to find potential drug therapeutic targets by comparing changes in the lipidome and related enzymes in cells or tissues in disease states and normal states. Lipid molecules that specifically bind to these target proteins may then become druggable lead compounds. Their structures are then analyzed and optimized to obtain new drug molecules acting on the target proteins drug mechanism of action studies.
Adverse drug reactions (ADRs), untoward outcomes of therapeutic drugs, occur along with their main therapeutic effect, thereby raise safety concerns in drug development and disease treatment. In severe cases of ADRs, both upcoming drugs and approved drugs are withdrawn. Therefore, biomarkers for ADR susceptibility, onset, severity, and recovery, have been a major focus of research in pharmacology and toxicology. FAs, GLs, GPs, SLs, and STs are relatively abundant in the mammalian body and are the major targets of lipidomics used to identify biomarker candidates for diseases and organ toxicities, including ADRs.
Another potential lipidomic biomarker application area is the identification of drug efficacy biomarkers. With the improvement of the ability to detect low abundance lipid molecule species, the evaluation of lipid markers for drug efficacy will be discovered. Monitoring the changes of lipid metabolism in the body after drug action, and timely response to changes in the physiological and biochemical status of the body, will help to evaluate the efficacy of drugs and identify possible side effects.
Lipidomic analysis based on GC-MS and LC-MS has great potential for application in all these fields. Creative Proteomics provides lipidomic biomarker analysis services to accelerate your project.
Available Services
How we work in 7 easy steps
Creative Proteomics provides a perfect lipidomics platform for biomarker analysis. If you have any special needs for biomarker analysis, please contact us. Let us know what you need and we will accommodate you. We look forward to working with you in the future.
References:
- Dehairs, J.; et al. Lipidomics in drug development. Drug Discovery Today: Technologies. 2015, 13, 33-38.
- Zhao YY.; et al. Lipidomics applications for discovering biomarkers of diseases in clinical chemistry. Int Rev Cell Mol Biol. 2014, 313:1-26.
* Our services can only be used for research purposes and Not for clinical use.
Applications:
